Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
REDWOOD CITY, Calif., Sept. 06, 2016 -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at two upcoming investor conferences:
- The Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 12:05 PM ET at the Lotte New York Palace Hotel.
- The 2016 Aegis Capital Growth Conference on Wednesday, September 21, 2016 at 11:00 AM PT at the Wynn Las Vegas.
The presentations will be webcast live and may be accessed by visiting the “Events & Presentations” section of the Company's website at www.capnia.com. The webcasts will also be available on the Company’s website for a limited period of time following the conferences.
About Capnia
Capnia is a leading provider and developer of innovative healthcare products used for the screening, detection and treatment of medical conditions. Capnia’s flagship products, Serenz® Allergy Relief and CoSense® ETCO Monitor, are based on its proprietary technologies, which utilize precision metering of gas flow. Capnia currently markets Serenz Allergy Relief in the UK and Ireland. The CoSense ETCO Monitor, which measures end-tidal carbon monoxide (ETCO) that can be used to detect hemolysis, and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants, are marketed globally. Capnia is also clinically evaluating its nasal, non-inhaled CO2 technology to treat trigeminally-mediated pain conditions such as cluster headache and trigeminal neuralgia. For more information, please visit www.capnia.com.
Investor Relations Contact: Michelle Carroll/Susie Kim Argot Partners (212) 600-1902 [email protected] [email protected]
